Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave ablation combined with autologous AFK cell therapy for advanced non-small cell lung cancer
ChiCTR2000029191Phase 2Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jan 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous AFK cells in non-small cell lung cancer (NSCLC), sponsored by Beijing Hospital. Primary endpoint: Effectiveness. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
autologous AFK cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000029191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029191.